During the Reuters Event Pharma 2024 in Barcelona, both days have been packed with discussions on how Artificial Intelligence (AI) and disease-modifying and curative therapies will reshape healthcare, challenging existing value assessment and payment models. The call to revamp value assessment frameworks is loud, emphasising the importance of recognising value amidst evolving landscapes.
Harmonising Health Technology Assessment (HTA) requires caution, given the significant disparities in current systems, addressing healthcare fragmentation is crucial, with AI touted as a supportive tool in these areas, not a decision-maker. Managing GDPR concerns as AI delves into vast interconnected data sources will likely become a key focus.
The appetite to navigate these transformative shifts together to ensure sustainable healthcare provision and innovation is there, let’s make it happen!
#REPharma2024
#HealthcareInnovation
#AI
#ValueAssessment
